Intracoronary Infusion of Autologous CD133+ Cells in Myocardial Infarction and Tracing by Tc99m MIBI Scintigraphy of the Heart Areas Involved in Cell Homing

Ubaidullo Kurbonov,Abdusamad Dustov,Alijon Goibov,Amu Therwath,Navjuvon Navjuvonov,Oktam Bobokhojaev,Alisher Barotov,Bakhtovar Karim-Zade,Giesidin Mirojov,Sohibnazar Rakhmonov,Eraj Rizoev,Mukim Rakhmatov,Zikrie Rahimov,Suhayli Muminjonov,Massoud Mirshahi,Jamila Irgasheva,Т Г Гульмурадов ,Н Х Олимов ,Azadeh Didari,Murtazokul Khidirov

doi:10.1155/2013/582527

Abstract

CD133 mesenchymal cells were enriched using magnetic microbead anti-CD133 antibody from bone marrow mononuclear cells (BMMNCs). Flow cytometry and immunocytochemistry analysis using specific antibodies revealed that these cells were essentially 89 ± 4% CD133+ and 8 ± 5% CD34+. CD133+/CD34+ BMMNCs secrete important bioactive proteins such as cardiotrophin-1, angiogenic and neurogenic factors, morphogenetic proteins, and proinflammatory and remodeling factors in vitro. Single intracoronary infusions of autologous CD133+/CD34+ BMMNCs are effective and reduce infarct size in patients as analyzed by Tc99m MIBI myocardial scintigraphy. The majority of patients were treated via left coronary artery. Nine months after cell therapy, 5 out of 8 patients showed a net positive response to therapy in different regions of the heart. Uptake of Tc99 isotope and revitalization of the heart area in inferoseptal region are more pronounced (P = 0.016) as compared to apex and anterosptal regions after intracoronary injection of the stem cells. The cells chosen here have the properties essential for their potential use in cell therapy and their homing can be followed without major difficulty by the scintigraphy. The cell therapy proposed here is safe and should be practiced, as we found, in conjunction with scintigraphic observation of areas of heart which respond optimally to the infusion of autologous CD133+/CD34+ BMMNCs.

Highlights

Heart failure is the leading cause of death worldwide, and current therapies only delay progression of the disease
The regions of anterior and septal of the heart were strongly revitalized (Figure 4(b)). This patient was treated by 52 × 104 CD133+/CD34+ bone marrow mononuclear cells (BMMNCs), and the cells were introduced by left coronary artery (LCA)
Revitalization was observed in all these regions (see Figure 4(b)). This patient was treated by 68 × 104 CD133+/CD34+ BMMNCs, and the cells were introduced by right coronary artery (RCA)

Summary

Introduction

Heart failure is the leading cause of death worldwide, and current therapies only delay progression of the disease. Source of stem cell therapy for heart disease may come from progenitors from hematopoietic (BM, peripheral blood, umbilical cord blood), mesenchymal (BM, adipose tissues), skeletal (muscle), endothelial (BM, peripheral blood), and cardiac (infarct border, epicardium) cells [5]. These cells are characterized by a high potential of pluripotent activity and can participate in tissues remodeling by secretion of growth factors in an autocrine or paracrine manner. When these cells are infused immediately in patients with coronary heart disease and postinfarction cardiosclerosis, they are able to modify revitalization of infarct scar as explored by scintigraphy

Material and Methods

Results

Discussion